REFERENCES
- Jemal A., Tiwari R. C., Murray T., Ghafoor A., Samuels A., et al. Cancer statistics. 2004. CA Cancer J. Clin. 2004; 54: 8–29, [INFOTRIEVE], [CSA]
- Poon R. T.P., Fan S. T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 2001; 19: 1207–1225, [INFOTRIEVE], [CSA]
- Fontanini G., Faviana P., Lucchi M., Boldrini L., Mussi A., et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavorable prognosis in operated small cell lung carcinoma. Br. J. Cancer. 2002; 86: 558–563, [INFOTRIEVE], [CSA], [CROSSREF]
- Eerola A. K., Soini Y., Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin. Cancer. Res. 2000; 6: 1875–1881, [INFOTRIEVE], [CSA]
- Kondo S., Asano M., Matsuo K., Ohmori I., Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta. 1994; 1221: 211–214, [INFOTRIEVE], [CSA], [CROSSREF]
- Yamamoto Y., Toi M., Kondo S., Matsumoto T., Suzuki H., et al. Concentrations of vascular growth factor in the sera of normal controls and cancer patients. Clin. Cancer. Res. 1996; 2: 821–826, [INFOTRIEVE], [CSA]
- Salven P., Ruotsalainen T., Mattson K., Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int. J. Cancer. 1998; 79: 144–146, [INFOTRIEVE], [CSA], [CROSSREF]
- Mall J. W., Schwenk W., Philipp A. W., Meyer-Kipker C., Mall W., et al. Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology. 2002; 7: 99–102, [INFOTRIEVE], [CSA], [CROSSREF]
- Takigawa N., Segawa Y., Fujimoto N., Hotta K., Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer. Res. 1998; 18: 1251–1254, [INFOTRIEVE], [CSA]
- Lucchi M., Mussi A, Fontanini G, Faviana P, Ribechini A., et al. Small cell lung carcinoma: the angiogenic phenomenon. Eur. J. Cardiothorac. Surg. 2002; 21: 1105–1110, [INFOTRIEVE], [CSA], [CROSSREF]
- Dowell J., Amirkhan R., Lai W., Minna J. Survival in small cell lung cancer (SCLC) is independent of vascular endothelial growth factor (VEGF) and cyclooxygenase (COX2) expression. Proc. Am. Soc. Clin. Oncol. 2003; 22: 632, [CSA]
- Xie K. Interleukin-8 and human cancer biology. Cytokine. Growth. Fac. Rev. 2001; 12: 375–391, [CSA], [CROSSREF]
- Koch A. E., Polverini P. J., Kunkel S. L., Harlow L. A., Dipietro L. A., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992; 258: 1798–1801, [INFOTRIEVE], [CSA]
- Smith D. R., Polverini P. J., Kunkel S. L., Orringer M. B., Whyte R. I., et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med. 1994; 179: 1409–1415, [INFOTRIEVE], [CSA], [CROSSREF]
- Arenberg D. A., Kunkel S. L., Polverini P. J., Glass M., Burdick M. D., et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small-cell lung cancer in SCID mice. J. Clin. Invest. 1996; 97: 2792–2802, [INFOTRIEVE], [CSA]
- Yuan A., Yang P. C., Yu C. J., Chen W. J., Lin, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor prognosis, tumor angiogenesis, patient survival, and timing of relapse in non-small cell lung cancer. Am. J. Respir. Crit. Care. Med. 2000; 162: 1957–1963, [INFOTRIEVE], [CSA]
- Masuya D., Huang C., Liu D., Kameyama K., Hayashi E., et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in non-small cell lung carcinoma patients. Cancer. 2001; 92: 2628–2638, [INFOTRIEVE], [CSA], [CROSSREF]
- Chen J. J.W., Yao P. L., Yuan A., Hong T. M., Shun C. T., et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin. Cancer. Res. 2003; 9: 729–737, [INFOTRIEVE], [CSA]
- Orditura M., DeVita F., Catalano G., Infusino S., Lieto E., et al. Elevated serum level of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J. Interferon. Cytokine. Res. 2002; 22: 1129–1135, [INFOTRIEVE], [CSA], [CROSSREF]
- Yatsunami J., Tsuruta N., Ogata K., Wakamatsu K., Takayama K., et al. Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung. Cancer. Lett. 1997; 120: 101–108, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhu Y. M., Webster S. J., Flower D., Woll P J. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br. J. Cancer. 2004; 91: 1970–1976, [INFOTRIEVE], [CSA], [CROSSREF]